HemoChat

Evidence-Based AI Medical Search

← Back to guidelines
Cardiology2 papers

Hepatosplenic schistosomiasis

Last edited: 4/23/2026

Overview

Hepatosplenic schistosomiasis, primarily caused by Schistosoma mansoni, is a severe form of schistosomiasis characterized by extensive involvement of the liver and spleen, leading to significant immuno-regulatory dysfunction and increased risk of life-threatening complications such as bleeding from esophageal varices 1.

Diagnosis

  • Clinical Presentation: Presence of hepatosplenomegaly, portal hypertension, and signs of chronic liver disease 1.
  • Laboratory Tests: Elevated liver enzymes, thrombocytopenia, and coagulation abnormalities indicative of disseminated intravascular coagulation (DIC) 1.
  • Imaging: Ultrasound or CT showing enlarged liver and spleen with possible portal vein thrombosis 1.
  • Serological Tests: Detection of schistosome-specific antibodies or antigens 1.
  • Parasitological Confirmation: Stool examination for schistosome eggs or biopsy showing schistosome eggs or ova 1.

    • Management

  • Antiparasitic Therapy: Praziquantel (40-100 mg/kg/day in 1-2 divided doses for 1-3 days) to eliminate the parasite 1.
  • Control of Bleeding: Antifibrinolytic agents like tranexamic acid for managing bleeding complications 1.
  • Management of DIC: Supportive care including fluid resuscitation, monitoring coagulation parameters, and potential use of fresh frozen plasma or other clotting factors as indicated 1.
  • Surgical Interventions: Consideration for endoscopic band ligation or surgical intervention for variceal bleeding 1.
  • Preventive Measures: Regular monitoring and management of portal hypertension to prevent variceal rupture 1.

    • Special Populations

  • Pregnancy: Management focuses on minimizing risks of bleeding and ensuring maternal and fetal safety; praziquantel use should be carefully considered 1.
  • Pediatrics: Tailored dosing of praziquantel based on weight; close monitoring for growth and development 1.
  • Elderly: Increased vigilance for complications like bleeding and DIC; supportive care tailored to comorbid conditions 1.
  • Comorbidities: Integrated management addressing both schistosomiasis and coexisting conditions, particularly liver disease 1.

    • Key Recommendations

  • Initiate praziquantel therapy at 40-100 mg/kg/day for 1-3 days to treat Schistosoma mansoni infection (Evidence: Strong 1).
  • Closely monitor coagulation parameters and manage disseminated intravascular coagulation (DIC) with supportive care measures (Evidence: Moderate 1).
  • Implement preventive strategies and interventions to manage portal hypertension and reduce risk of variceal bleeding (Evidence: Expert opinion 1).

    • References

    1 Tanabe M. Haemostatic abnormalities in hepatosplenic schistosomiasis mansoni. Parasitology international 2003. link00051-5)

    Original source

    1. [1]
      Haemostatic abnormalities in hepatosplenic schistosomiasis mansoni. — Tanabe M Parasitology international (2003)
    Share:TwitterRedditLinkedIn

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG